Thrombus - 2010

Guidelines on lupus anticoagulant screening
Ian Jennings
pp 1-4
Guidelines on lupus anticoagulant (LA) screening or testing have been regularly published for over 25 years. This article reviews the history of LA guidelines, and a subsequent article will indicate what is new in the latest guidelines, which were published in the Journal of Thrombosis and Haemostasis in October 2009. Antiphospholipid syndrome (APS) is associated with venous thromboembolic disease, arterial occlusive events and pregnancy morbidity.

Comment: Is it really as simple as ABCD?
Peter Rose
pp 2-2
To help stratify patients at risk of stroke, several clinical algorithms have been developed. These have the potential to enable preventative measures to be set in place to reduce stroke events and also to identify patients likely to have the most serious outcomes. Triaging the appropriate patients with transient ischaemic attacks (TIAs) for more interventions is an equally important consideration. Atrial fibrillation (AF) is well known to be associated with cardiovascular disease and adverse stroke outcomes.

Update on the management of acute venous thromboembolism
Martin Lewis and Jennie Wimperis
pp 5-7
Acute venous thromboembolism (VTE) has an annual incidence of approximately one to two per 1,000 in adults and is the third most common cause of vascular mortality after myocardial infarction and stroke. The House of Commons Health Committee reported in 2005 that, every year, an estimated 25,000 people in the UK die from preventable hospital-acquired VTE, making this the leading cause of preventable inpatient mortality.

Evidence against low molecular weight heparin for superficial thrombophlebitis
Louise Fryearson
pp 8-9
Superficial thrombophlebitis (ST) usually comprises pain, localised erythema and swelling, and is commonly associated with varicose veins. Superficial venous thrombosis (SVT) may be a consequence of ST, and the terms are used interchangeably throughout the literature. ST is often considered a benign and self-limiting condition. Patient presentation to healthcare professionals is highly variable and, consequently, there is no clear incidence data for this condition.

Accuracy of prescribing therapeutic doses of enoxaparin
Uttamlal Chouhan, Matthew Bevan and Jillian Simpson
pp 10-11
The various forms of low molecular weight heparin (LMWH) are now the heparin of choice for the treatment of venous thromboembolism (VTE) and acute coronary syndrome (ACS), replacing the previously routine use of unfractionated heparin (UFH). Treatment for both VTE and ACS is initiated as an emergency by junior medical staff in training. There is developing evidence for the poor accuracy of prescribing of LMWH in hospital practice.

A nurse-led approach to risk assessment
Adam Howard and James AG Madden
pp 12-15
Venous thromboembolism (VTE) – incorporating pulmonary embolism (PE) and deep vein thrombosis (DVT) – is one of the most common complications of hospitalisation, leading to mortality, a short- and long-term increase in morbidity and increased costs. VTE is responsible for an estimated 24,000–32,000 deaths a year in the UK, with the majority of fatal PE occurring in non-surgical patients. There has been extensive evidence presented in literature over the last 50 years to suggest that the use of thromboprophylaxis is cheap, effective and safe, with significant reductions in the number of cases of PE and DVT.

Spring 2010, Volume 14 Number 1

Winter 2010, Volume 13 Number 4

Thrombus was previously supported by Bayer from 2014 to 2016, by Boehringer Ingelheim from 2009 to 2013, by sanofi-aventis from 2007 to 2008 and by Leo Pharma from 1998 to 2006.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsor, publisher, Editor or Editorial Board. Accordingly the sponsor, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Thrombus is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2019 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk

ISSN 1369-8117 (Print) ISSN 2045-7855 (Online)